A couple of contract research organizations are expanding manufacturing operations, including one responding to increased demand for biologic products.
CoreRx will invest $2 million to expand its manufacturing operations in Clearwater, FL. The work includes a new facility for hormone development, clinical trial manufacturing and commercial manufacturing capabilities. The company said it will add 25 employees to its workforce over time.
The company said it acquired a site that will allow for 40,000 square feet of additional manufacturing, as well as office facilities. The new facility will include three suites. Work is slated to start next month and be completed by the middle of the fourth quarter. It completed expansion on its initial site last year.
At the same time, Cytovance Biologics, a contract manufacturer of mammalian and microbial biologics, said it is expanding the microbial manufacturing capabilities at its Oklahoma City operation.
Contract manufacturing and research organizations have been beefing up their biologics capabilities around the globe as more new drugs require those services. In November Innovent Biologics said it would take $25 million from interested investors and intends to plow some of that into a commercial-scale biologics plant in Suzhou, China. In fact, Innovent boasts that the facility will be the largest GMP compliant biologics plant in China.
- here's the CoreRX release
- see the Cytovance Biologics release